台灣臨床試驗主持人資料庫|TPIDB

2017-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Condition/Disease

Moderate to Severe Atopic Dermatitis
Test Drug

Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2015-07-01 - 2022-12-31

Phase III

Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib

Condition/Disease

Hepatocellular Carcinoma
Test Drug

Ramucirumab (Cyramza)

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

黃怡翔

Taipei Veterans General Hospital

Digestive System Department

2015-09-15 - 2019-02-28

Phase II

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Condition/Disease

Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Test Drug

Ramucirumab

Participate Sites
6Sites

Terminated5Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

白禮源

China Medical University Hospital-Taipei

未分科

2018-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate to Severe Atopic Dermatitis BREEZE-AD7

Condition/Disease

Moderate to Severe Atopic Dermatitis
Test Drug

Baricitinib (LY3009104)

Participate Sites
5Sites

Terminated5Sites

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2016-04-16 - 2018-12-31

Phase III

Condition/Disease
Test Drug

Participate Sites
4Sites

Terminated2Sites

張廷彰

Linkou Chang Gung Medical Foundation

未分科

2015-09-01 - 2016-12-31

Phase I

Condition/Disease
Test Drug

Participate Sites
3Sites

Terminated3Sites

邱政洵

Linkou Chang Gung Medical Foundation

Division of Pediatrics

2017-07-01 - 2020-08-22

Phase II

A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)

Condition/Disease

Recurrent or Progressive Glioblastoma following Initial Therapy
Test Drug

DSP-7888

Participate Sites
3Sites

Recruiting3Sites

魏國珍

Linkou Chang Gung Medical Foundation

Division of Orthopedics

2016-11-01 - 2019-07-31

Phase III

A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

Condition/Disease

High Risk Locally Advanced Cervical Cancer
Test Drug

ADXS11-001

Participate Sites
6Sites

Terminated6Sites

張廷彰

Linkou Chang Gung Medical Foundation

Division of Obstetrics & Gynecology

2015-09-01 - 2021-02-19

Phase II

A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment.

Condition/Disease

moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma
Test Drug

PDR001

Participate Sites
4Sites

Not yet recruiting1Sites

Terminated3Sites

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-01-15 - 2020-01-31

Others

Condition/Disease
Test Drug

Participate Sites
2Sites

Terminated2Sites

侯明模

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

Search Result

List